Skip to content

Enabling the Future of Medicine

World Changing. Life Saving. For Good.

NTx was founded to democratize access to medicines by enabling on-demand, decentralized biomanufacturing. For too long, the development of vital therapies has been hindered by slow, complex, and centralized production methods. We were created to overcome these barriers.

Our proprietary platforms utilize cell-free synthetic biology in a continuous flow system, giving researchers and drug developers unprecedented speed and control. This approach allows for the scalable production of high-integrity mRNA and proteins, accelerating timelines from discovery to commercial manufacturing. We provide the tools that clear the path from concept to cure, empowering our partners to build the future of medicine.

NTx Bio is redefining biomanufacturing to accelerate therapeutic breakthroughs. Our innovative NTxscribe® and NTxpress® platforms empower scientists worldwide by delivering accessible, high-quality, and rapidly scalable production solutions, ultimately helping bring life-saving treatments to patients faster.

SUSTAINABLE

Our biosynthesis technology is completely defined and is independent of cell lines

CONSISTENT

Our results are reproducible with limited artifacts

SCALABLE

Our biomanufacturing processes can be easily scaled to meet fluctuating supply needs

BIOSYNTHETIC

Our platforms are built for cell-free mRNA and protein production

EFFICIENT

Rapid, high-quality, and low-cost production to accelerate lead optimization, pre-clinical testing and IND filings

Executive Team

JC
James M. Coffin, PhD
President & Chief Executive Officer
SE
Steven Evans, PhD
Chief Scientific Officer & Senior Vice President R&D
 
MR v2
Marcel Roche
Chief Financial Officer
Joan Haab
Chief Operating Officer
MP v2
Matthew Phillips
Senior Vice President, Business Development
 Aaron Leopold
Vice President, Corporate Development
DK2
Daniel Kreamer
Vice President, Quality Assurance
JT
Jason Tong
Vice President, Sales Operations and Customer Support
PEPhillip Easton, PhD
Vice President, IT Infrastructure & Operations 
HYHandy Yowanto
Vice President, Product Management

Board of Directors

JC
President & Chief Executive Officer
PKPeter Kolchinsky, PhD
Managing Partner, RA Capital Management
Former Chairman & CEO, Allstate Corporation
Managing Principal, Camino Real Capital Partners
DS updated
Managing Partner, Anzu Partners
David Johnson
Senior Partner, TLG Holding

Scientific Advisory Board

Scientific Advisory Board, Chair 
Yale School of Medicine 
Houston Methodist Research Institute
Mayo Clinic
Icahn School of Medicine at Mount Sinai
Penn State Health /
Beat Childhood Cancer Research Consortium
University of Florida
MD Anderson Cancer Center
Dana Farber Cancer Institute